Siponimod (BAF-312) is an orally active, blood-brain barrier penetrant dual agonist of S1P1 / S1P5 , with EC 50 values of 0.39 nM and 0.98 nM, respectively. Siponimod induces S1P1 internalization, activates GIRK channels, inhibits lymphocyte egress, reduces peripheral lymphocyte counts, triggers transient bradycardia, prevents synaptic neurodegeneration, promotes remyelination, alleviates demyelination, and prevents the loss of GABAergic interneurons. Siponimod can be used in research related to multiple sclerosis.
Products | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > CNS Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Disease Areas > Experimental Autoimmune Encephalomyelitis | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > LPL Receptor | Products > Signaling Pathways > Potassium Channel
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.